Novanta sees Q2 adjusted EPS 68c-78c, consensus 75c

Sees Q2 revenue $230M-$240M, consensus $240.74M. “Novanta (NOVT) has a solid track record of delivering and even accelerating out of uncertain environments by overcoming challenges and seizing opportunities. We are confident in our ability to excel by utilizing the Novanta Growth System, which emphasizes innovation, operational excellence, strategic alignment, and winning in high-growth markets. Our focus is on near-term execution, including launching new breakthrough products, while at the same time investing in and advancing our growth strategy in markets with long-term secular growth trends like precision robotics and automation, minimally invasive and robotic surgery, and precision medicine,” said Matthijs Glastra.